Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Asphelia Pharmaceuticals, Inc.
San Diego, California, United Statesaspheliapharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Asphelia Pharmaceuticals developed novel therapeutics targeting immunological and inflammatory diseases. Its lead programs included ASP‑1001 nasal spray for allergic rhinitis and Trichuris Suis Ova therapy for Crohn's disease. Clinical trials reached up to Phase 2/3, with at least one trial completed. The company was acquired by Coronado Biosciences/Fortress Biotech around or before the early/mid‑2010s, and does not appear to be independently active today.
- Therapeutic areas
- GastroenterologyImmunology
- Modalities
- Small moleculesBiological therapy
- Industry
- Biotech
02
Partnerships
University of Chicago collaborated on clinical trial of ASP‑1001; no major pharma partnerships disclosed
Beyond the preview
Go deeper on Asphelia Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Asphelia Pharmaceuticals, Inc..